{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-005521","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.832118+00:00","generated_at":"2026-05-27T20:28:30.320899+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Onconetix settles IQVIA dispute for $150k, records $0.9M reduction in accounts payable","bullets":["Resolved IQVIA dispute with $150k payment, avoiding claimed $1.09M liability.","Mutual release of all claims under the Master Services Agreement; no admission of liability.","Company to reduce accounts payable by approximately $0.9 million as a result of settlement.","Proteomedix subsidiary posted on LinkedIn about Proclarix study for clinically significant prostate cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-005521","json":"https://secwatch.observer/filing/0001213900-25-005521.json","markdown":"https://secwatch.observer/filing/0001213900-25-005521.md","text":"https://secwatch.observer/filing/0001213900-25-005521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025005521/0001213900-25-005521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025005521/ea0228132-8k_onconetix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T20:28:30.320899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}